What changed from existing technology?
This study shows that small vesicles in the blood of head and neck cancer patients can make T-cells, which are important for fighting cancer, stop working properly.
This is the first study to show that plasma sEVs from HNC patients directly alter T-cell function and immune checkpoint expression, potentially explaining treatment resistance.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
lular vesicles from the plasma of head and neck cancer patients induce dysfunctional T cell phenotypes. Head and neck cancer (HNC) is highly immunosuppressive
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
These findings suggest plasma sEVs could serve as biomarkers for immune dysfunction in HNC, but clinical applications require further validation.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.